Results 141 to 150 of about 10,881,142 (301)

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Understanding the key differences between ISO 15189:2022 and ISO 15189:2012 for an improved medical laboratory quality of service

Romanian Journal of Laboratory Medicine, 2023
Ilinca Radu, Chiriac Ionuț A., Luțescu Dan A., Ganea Ionela, Hristodorescu-Grigore Smaranda, Dănciulescu-Miulescu Rucsandra-Elena   +5 more
doaj   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Cybersecurity requirement of ISO 15189 - a simplified protocol for laboratories

Romanian Journal of Laboratory Medicine, 2023
Ilinca Radu, Luțescu Dan Adrian, Chiriac Ionuț Adrian, Hristodorescu-Grigore Smaranda, Stănescu-Spînu Iulia-Ioana, Ganea Ionela, Gherlan Iuliana, Dănciulescu-Miulescu Rucsandra-Elena   +7 more
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

Molecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu, Puspa Das, Xing Zhang, Xiaodong Cheng   +3 more
wiley   +1 more source

A STUDY OF SIMULTANEOUS ELECTRIC ACTIVITIES OF PAIN--EXCITATIOM AND PAIN--INHIBITION NEURONS IN PREOPTIC AREA AND PARAFASCICULAR NUCLEUS IN RATS

针刺研究, 1984
Li Yurong, Zhang Jiye, Sun Mingzhi Acupuncture Research Laboratory of Harbin Medical College   +2 more
doaj   +2 more sources

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

The Role of the Medical Laboratory in Identifying 'Super-Spreaders': Correlation Between Viral Load Kinetics and Human-to-Human Infectivity. [PDF]

Rev Med Virol
Gupta Y, Verma A, Bhardwaj Y, Rastogi M, Katiyar A.   +4 more
europepmc   +1 more source

The medical laboratory scientist in the clinical chemistry service laboratory.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1983
The recent opening of an official register for medical laboratory scientists in South Africa has prompted an examination of the professional role, training and qualification of one particular group of scientists, namely clinical chemists working in hospital pathology departments.
openaire   +2 more sources

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source